{"id":"valproate-levocarnitine","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Weight gain"},{"rate":"5-10%","effect":"Hair loss"},{"rate":"1-5%","effect":"Liver enzyme elevation"},{"rate":"<1%","effect":"Pancreatitis"},{"rate":"<1%","effect":"Thrombocytopenia"},{"rate":"<1%","effect":"Leukopenia"}]},"_chembl":{"chemblId":"CHEMBL433","moleculeType":"Small molecule","molecularWeight":"166.20"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Valproate is thought to exert its effects by inhibiting the reuptake of certain neurotransmitters, such as serotonin and dopamine, and by reducing the release of excitatory neurotransmitters. Levocarnitine plays a crucial role in the transport of fatty acids into mitochondria, where they can be used as energy sources.","oneSentence":"Valproate is a mood stabilizer that works by reducing the activity of certain brain chemicals, while Levocarnitine is involved in energy production within cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:51:01.718Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seizure prevention, Mania treatment"}]},"trialDetails":[{"nctId":"NCT00227266","phase":"PHASE2","title":"Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy","status":"COMPLETED","sponsor":"University of Utah","startDate":"2005-09","conditions":"Spinal Muscular Atrophy","enrollment":94},{"nctId":"NCT00481013","phase":"PHASE2","title":"Valproic Acid in Ambulant Adults With Spinal Muscular Atrophy","status":"COMPLETED","sponsor":"University of Utah","startDate":"2007-07","conditions":"Spinal Muscular Atrophy","enrollment":33},{"nctId":"NCT01671384","phase":"PHASE3","title":"Valproate and Levocarnitine in Children With Spinal Muscular Atrophy","status":"UNKNOWN","sponsor":"All India Institute of Medical Sciences","startDate":"2013-08","conditions":"Spinal Muscular Atrophy","enrollment":60},{"nctId":"NCT00661453","phase":"PHASE1, PHASE2","title":"CARNIVAL Type I: Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy (SMA) Type I","status":"COMPLETED","sponsor":"University of Utah","startDate":"2008-04","conditions":"Spinal Muscular Atrophy Type I","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Valprol and carnisure"],"phase":"phase_3","status":"active","brandName":"Valproate, Levocarnitine","genericName":"Valproate, Levocarnitine","companyName":"All India Institute of Medical Sciences","companyId":"all-india-institute-of-medical-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Valproate is a mood stabilizer that works by reducing the activity of certain brain chemicals, while Levocarnitine is involved in energy production within cells. Used for Seizure prevention, Mania treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}